11SURPASS-CVOT: seguridad y eficacia cardiovascular en DM2 con ASCVD establecida SURPASS-CVOT (Nicholls et al., NEJM, diciembre 2025) es el primer ensayo aleatorizado, doble ciego y guiado por eventos que evala los resultados cardiovasculares con tirzepatida en pacientes con DM2 y ASCVD establecida
How Soon Do Research Models Show a Response to Retatrutide In Phase 2 clinical studies, measurable reductions in body weight were observed within the first four weeks of treatment, with the rate of weight loss continuing through 24 weeks before plateauing toward 48 weeks [8]
The IC 50 was calculated using a four-parameter dose-response inhibition model, with the bottom fit constrained to the lower plateau of the binding curve
The Zika Virus Epidemic in Brazil: From Discovery to Future Implications
Out-of-pocket costs for insured patients often reach $300-$500 monthly even with coverage, depending on deductible and coinsurance levels
Xarelto is a key production of Bayer and Johnsons which was approved in the year 2007 and is expected to expire in 2026
